ArticleScientific reports2026
A customized MobileNetV2-based lightweight CNN for monkeypox detection and classification.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (Mpox) is an infectious disease that can spread through physical contact or from infected animals and has historically been endemic to Africa, with major outbreaks recorded in 2022. More recently, it has spread worldwide, becoming a significant public health concern. Early detection, robust surveillance, and effective contact tracing are essential for controlling the spread of Mpox. In response, various approaches have been proposed for early detection; however, most existing methods lack both efficiency and high accuracy, making them less suitable for deployment on edge devices. This study introduces a customized MobileNetV2 (CMBNV2) lightweight model for the early detection of Mpox, which delivers excellent detection performance while maintaining efficiency. A customization to the original MobileNetV2 was applied by replacing the original classifier with a lightweight pooling dropout head. To enable the proposed model to capture Mpox features while preserving its efficiency for edge deployment, the researcher fine-tuned only the last 20 layers. The researcher utilized the publicly available Monkeypox Skin Image Dataset (MSID) from the Kaggle repository, consisting of 770 images across four categories: Monkeypox, Measles, Chickenpox, and Normal. The dataset was split into 70% for training and 30% for validation/testing. To address the challenges of limited data, overfitting, and generalization, data augmentation, weighted cross-entropy, and fine-tuning techniques were applied during training. The CMBNV2 was evaluated using multiple performance metrics, including accuracy, F1-score, precision, recall, and a confusion matrix. CMBNV2, with a size of only 8.63 MB, achieved an outstanding detection accuracy of 99%. Due to its lightweight design, the model can be easily deployed on edge devices such as smartphones, playing a crucial role in the early detection and control of Mpox spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.